Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Iclusig

- PMLiVE

Takeda ends obesity alliance with Amylin

Comes more than a year after development of lead product was pulled

- PMLiVE

Actavis mounts patent challenge on Velcade in US

Plans to launch own version of Takeda’s cancer drug

- PMLiVE

Eliquis and Ryzodeg feature among Japan’s year-end approvals

Actonel and Neupro also given green light

- PMLiVE

Early FDA approval for Ariad’s leukaemia drug Iclusig

Available in US three months ahead of schedule

- PMLiVE

Lundbeck and Takeda submit depression drug for US approval

Brintellix could help Lundbeck overcome loss of patent protection for Lexapro/Cipralex

- PMLiVE

Interview: Trevor Smith, Takeda

Takeda’s head of commercial operations for Europe and Canada talks about the integration of Nycomed and European market access

- PMLiVE

Takeda acquires US-based drug discovery company Envoy

Japanese pharma firm gains target identification technology and preclinical CNS assets

- PMLiVE

Acquisitions soften Actos blow in Takeda’s first-half results

URL Pharma and Nycomed purchases help sales increase 12 per cent to 787bn yen

Pharma must ’embrace the new reality’ and meet payers’ needs

This means capturing better health economic data during product development, says Takeda's Trevor Smith

- PMLiVE

Takeda pays $60m for vaccine company LigoCyte

Gains first-in-class norovirus candidate and new vaccine platform

- PMLiVE

Takeda completes new manufacturing facility in Russia

Expands Japanese firm’s presence in key emerging market

- PMLiVE

Takeda’s Revestive becomes first approved drug in Europe for short bowel syndrome

Can reduce dependency on intravenous feeding

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links